Drugs / DNAJB1-PRKACA Peptide Vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07430202 | Aug 2026 → Aug 2030 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04248569 | Apr 2020 → Mar 2029 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNAJB1-PRKACA peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04248569 ↗ |
| Known as | FLC-Vac | “Here we conducted a phase 1 clinical trial of a therapeutic peptide vaccine targeting DNAJ-PKAc (FLC-Vac), in combination with nivolumab and ipilimumab, in children and adults...” PMID 41286513 ↗ Nov 2025 |
| Modality | Vaccine | “therapeutic peptide vaccine” PMID 41286513 ↗ Nov 2025 |
| Target | DNAJB1 | “a vaccine targeting the DNAJB1-PRKACA fusion kinase” NCT04248569 ↗ |
| Target | PRKACA | “a vaccine targeting the DNAJB1-PRKACA fusion kinase” NCT04248569 ↗ |